GLAXO · NSE
GlaxoSmithKline Pharmaceuticals Limited
₹2,727.6
+0.52% (+₹14.2)
Prev. close
₹2,713.4
Volume
84,480
Delivery %
59.9%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) with a target price of ₹3,560 in two to three months, recomm…” | Marketsmith India AnalysisMarketsmith India | GlaxoSmithKline Pharmaceuticals Ltd | MISS | |
| “Bullish on GlaxoSmithKline Pharmaceuticals Ltd, recommending a buy at ₹3,156 with a target price of ₹3,560 in two to thr…” | Marketsmith India AnalysisMarketsmith India | GlaxoSmithKline Pharmaceuticals Ltd | MISS | |
| “Recommends buying GlaxoSmithKline Pharma with a target of ₹2,800 and a stop loss at ₹2,680, indicating a bullish outlook…” | Kunal BothraIndependent | GlaxoSmithKline Pharmaceuticals Ltd. | HIT | |
| “Bullish on GLAXO; recommends buying above ₹2760 with a stop loss at ₹2725 and targets of ₹2985-3025. Despite recent pres…” | Raja VenkatramanNeoTrader | GlaxoSmithKline Pharmaceuticals Limited | MISS | |
| “Recommends buying GLAXO above ₹2760 with a stop loss at ₹2725 and targets of ₹2985-3025. Despite general pressure on pha…” | Raja VenkatramanNeoTrader | GlaxoSmithKline Pharmaceuticals Limited | MISS | |
| “Bullish on Glaxo, recommending a buy at ₹2,638 with targets of ₹2725-2750 and a stop loss at ₹2,544. The stock shows bul…” | Ankush BajajIndependent | GlaxoSmithKline Pharmaceuticals Ltd. | HIT | |
| “Recommends buying Glaxo at ₹2,638 with targets of ₹2725-2750 and a stop loss at ₹2,544. The stock is exhibiting bullish …” | Ankush BajajIndependent | GlaxoSmithKline Pharmaceuticals Ltd. | HIT | |
| “Upgraded GlaxoSmithKline Pharmaceuticals to 'Add' from 'Hold' with a revised target price of ₹2,250 (previously ₹2,550),…” | ICICI Securities AnalysisICICI Securities | GlaxoSmithKline Pharmaceuticals Ltd. | PENDING | |
| “Recommends buying GlaxoSmithKline Pharmaceuticals at around ₹2018, targeting ₹2130 with a stop loss at ₹1970.” | Shiju KoothupalakkalPL Capital | GlaxoSmithKline Pharmaceuticals Ltd | PENDING |
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on GlaxoSmithKline Pharmaceuticals Ltd (GLAXO), recommending buying, holding, and accumulating. The stock shows …” | Rajesh PalviyaAxis Securities | GlaxoSmithKline Pharmaceuticals Ltd | — | |
| “Bullish on GlaxoSmithKline Pharmaceuticals, anticipating further upside towards ₹2,672-2,690, with ₹2,320 acting as stro…” | Vishnu Kant UpadhyayMaster Capital Services | GlaxoSmithKline Pharmaceuticals Ltd. | — |
Fundamentals
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Bhushan Akshikar
Headquarters
Mumbai
Employees
3,103
Website
india-pharma.gsk.comExchange
View on NSE ↗Key stats
Market cap
₹42,995.25 Cr
P/E ratio (TTM)
37.5
Dividend yield
2.21%
EPS (TTM)
₹67.68
Beta (1Y · daily vs NIFTY 50)
0.50
Beta (5Y · monthly vs NIFTY 50)
0.58
Shares float
4.13 Cr
EPS · quarter ended Jun 2026
₹14.00
Financial Performance
01 · Financials
EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,198.86 Cr | ₹3,278.03 Cr | ₹3,251.72 Cr | ₹3,453.71 Cr | ₹3,726.03 Cr | ₹3,821.67 Cr | |
EBITDA | ₹633.31 Cr | — | ₹903.98 Cr | ₹887.67 Cr | ₹1,327.98 Cr | ₹1,475.18 Cr |
| ₹358.15 Cr | ₹1,695.00 Cr | ₹610.69 Cr | ₹589.96 Cr | ₹927.58 Cr | ₹1,035.98 Cr | |
Diluted EPS | ₹21.14 | ₹100.04 | ₹36.05 | ₹34.83 | — | ₹61.15 |
Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹633.31 Cr while the annual report gives ₹805.91 Cr (27.3% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹736.26 Cr) and EBITDA for Mar 2022 (the annual report alone gives ₹837.66 Cr) are left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,115.00 Cr | ₹4,633.00 Cr | ₹3,327.00 Cr | ₹3,557.00 Cr | ₹4,108.00 Cr | ₹4,324.00 Cr | |
| ₹34.63 Cr | ₹20.08 Cr | ₹15.54 Cr | ₹18.67 Cr | ₹9.95 Cr | ₹33.27 Cr | |
Stockholders' equity | ₹1,478.00 Cr | ₹2,663.00 Cr | ₹1,741.00 Cr | ₹1,777.00 Cr | ₹1,951.00 Cr | ₹2,267.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹578.00 Cr | ₹811.00 Cr | ₹484.00 Cr | ₹582.00 Cr | ₹1,290.00 Cr | ₹903.00 Cr | |
Investing cash flow | ₹418.58 Cr | ₹-405.50 Cr | ₹807.85 Cr | ₹8.72 Cr | ₹-45.80 Cr | ₹396.98 Cr |
| ₹-696.00 Cr | ₹-524.00 Cr | ₹-1,543.00 Cr | ₹-562.00 Cr | ₹-769.00 Cr | ₹-737.00 Cr | |
Capital expenditure | ₹-44.00 Cr | ₹-35.00 Cr | ₹-44.00 Cr | ₹-31.00 Cr | ₹-23.00 Cr | ₹-55.00 Cr |
End cash position | ₹405.19 Cr | ₹286.19 Cr | ₹34.94 Cr | ₹64.17 Cr | ₹538.85 Cr | ₹1,102.05 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 75.00% |
| Public | 25.00% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| GlaxoSmithKline Pharmaceuticals Limited | ₹43,349.31 Cr | ₹2,531.4 | 40.6 | 19.12 | 45.7% | 0.01 | +2.2% | -3.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.